To assess vascular calcification in the patients of hypoparathyroidism using multidetector computed tomography scan

Pooja Agarwal*, Mahesh Prakash*, Manphool Singhal, Sanjay Kumar Bhadada¹, Yashdeep Gupta, Niranjan Khandelwal
Departments of Radiodiagnosis and Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh, India

ABSTRACT

Background: Our pilot data showed an increased intima media thickness in the patients with sporadic idiopathic hypoparathyroidism (SIH). Alteration in homeostasis of calcium, phosphate, and parathyroid hormone (PTH) may predispose to increase the risk of cardiovascular morbidity and mortality. The data on objective assessment of this increased risk is however lacking. Objective: To assess the effect of altered calcium, phosphate, and PTH homeostasis in the patients with SIH on coronary calcium score (a marker of increased vascular risk) by multidetector computed tomography scan (MDCT). Methods: In this case-control study, we measured coronary CT calcium score in 30 patients of SIH and compared with 40 age and sex matched healthy subjects. Correlation of coronary calcium score with biochemical parameters was evaluated. Results: Three of the 30 cases (10%) with SIH were found to have coronary artery calcification (CAC) of varying degree, whereas none of the control showed CAC (P = 0.07). The patients with CAC had significantly lower serum calcium levels (albumin corrected), as compared to the patients without CAC. Inverse correlation of CAC was found with serum calcium levels. No correlation was found with other biochemical parameters. Conclusion: The vascular risk is increased in the patients with SIH as assessed by coronary calcium score measured by MDCT. Low serum calcium levels might be a predisposing factor for this increased risk.

Key words: Cardiovascular risk, coronary calcium scores, coronary computed tomography, hypoparathyroidism, multidetector computed tomography scan

INTRODUCTION

Hypoparathyroidism is a rare metabolic bone disease that commonly presents with neurological manifestations and is biochemically characterized by hypocalcemia, hyperphosphatemia, and low or low normal parathyroid hormone (PTH) level.[1] This situation is almost similar to chronic kidney disease (CKD) (low calcium and high phosphate) however; the major difference is low serum PTH in hypoparathyroidism. Changes in calcium, phosphate, and PTH homeostasis is a predisposing factor for vascular calcification and increases the risk of cardiovascular disease (CVD).[2,3] Plethora of literature is available for abnormal calcium homeostasis, relative hypoparathyroidism, increased vascular calcification and its correlation with increased cardiovascular events but are mainly in relation to end-stage renal disease patients.[2-8]

The increase in calcium and phosphate product in the patients with CK promotes the vascular calcification via multiple mechanisms. This may explain the alarmingly
The CAC score is strongly correlated with the overall atherosclerotic burden and has highly reproducible results. [18]

Methods

Patient selection
The study comprised of 30 consecutive patients with SIH attending the endocrine clinic of a tertiary care hospital, from January 2012 to May 2013. Forty age and sex matched healthy individuals were taken as control. The study was approved by the Institutional Ethics Committee. Written informed consent was taken from each subject.

The diagnosis of SIH was based on hypocalcemia and hyperphosphatemia associated with low or low normal PTH level. The exclusion criteria was: Patients with history of postoperative hypoparathyroidism or autoimmune polyendocrinopathy syndromes; subjects with history of smoking or any other chronic illness including hypertension, diabetes, dyslipidemia, obesity, deranged renal function, patient on antiepileptic drugs; patients with coronary metallic stents and presence of arrhythmia such as frequent extrasystole or uncontrolled atrial fibrillation.

Office blood pressure was measured in the sitting posture after 15–20 min of rest in the right arm twice and mean of two was taken for the calculation. Blood samples were collected in fasting status prior to any medications between 0800 and 0900 h by venepuncture from antecubital fossa (without tourniquet application) by a technician. Blood samples for the estimation of PTH were centrifuged immediately and processed and stored at −20°C in cases of anticipated delay in processing, till the time of analysis.

Laboratory methods

Serum PTH (reference range [RR], 15–65 pg/mL) was measured by chemiluminescence assay using commercially available kits (DiaSorin Inc., Stillwater, MN, USA) and rest of biochemical parameters (corrected serum calcium [RR, 2.2–2.6 mmol/L], inorganic phosphate [RR, 0.9–1.5 mmol/L], serum albumin [RR, 34–48 g/L], and total cholesterol [RR, 3.9–5.2 mmol/L], high density lipoprotein cholesterol [0.9–1.4 mmol/L], and low density lipoprotein cholesterol [0.8–2.6 mmol/L]) were measured by auto analyzer (Roche diagnostics, Modular P 800).

Coronary artery calcification measurement

CAC scores were evaluated by using Toshiba Aquilion computed tomographic scanner (Nasu, Japan; 64 sets of detectors) and Aquarius iNtuition edition, version 4.4.5.49.2104 software package (Vital Images Inc., Minnetonka, MN, USA). The data acquisition parameters were 120 KVP voltage, 300 mAs currents, and slice width 3.0 mm, DFOV 320.0 and gantry rotation time 0.25. The scan was taken from carina till the apex of the heart. The calcium score was calculated by algorithm suggested by Agatston et al. by determining the density of the highest density pixel in each plaque and applying a weighting factor to each plaque, dependent upon the peak density in the plaque: (Area × cofactor; 1: 130–199H; 2: 200–299H; 3: 300–399H; 4: >400H). [19] All pixels with density >130H are automatically highlighted in color on the images. An electronic region of interest was placed around each highlighted CAC and assigned one of four locations to each calcified plaque: Left main left anterior descending, circumflex or right coronary.

For interpretation of the Agatston scores, certain guidelines have been proposed for the asymptomatic persons with correlations between plaque burdens, the probability of significant CAD, implications for cardiovascular risk, and recommendations for treatment [Table 1]. [20] Calcium scores have the greatest negative predictive value. When they are either absent or low (<10 for Agatston scoring), it almost certainly indicates the low risk for the development of coronary heart disease. [21]
Statistical analysis
The statistical analysis was carried out using SPSS dear (version 17, SPSS, Chicago, IL, USA). Normality of data was checked by Kolmogorov–Smirnov test. For normally distributed data means were compared using independent -test for two groups. For skewed data, Mann–Whitney test was applied. Categorical variables were described as frequencies and proportions. Proportions were compared using Chi-square. Pearson’s correlation was used to correlate the clinical and biochemical variables with CAC in SIH and control group. All statistical tests were two-sided and performed at a significance level of $P < 0.05$. The data are presented as mean ± standard deviation unless otherwise specified.

RESULTS

Baseline characteristic of study population
Thirty subjects (13 men) with SIH and 40 age and sex matched healthy subjects (14 men) were included in this study. The mean age of the patients included in our study was 30.5 ± 6.5 years (range 15–39 years) whereas the age of healthy controls was 32.9 ± 4.1 years (range 21–40 years). Baseline characteristic of two groups are shown in Table 2. The mean total serum calcium, intact PTH levels were significantly lower and the value of serum phosphate levels significantly higher in the patients with SIH than in controls [Table 2].

Coronary artery calcification
Three of the 30 cases (10%) with SIH were found to have showed CAC of varying degree, whereas none of the control showed CAC ($P = 0.07$). The CAC score in these three patients (cases) were 120.13 (moderately high plaque burden) [Figure 1], 209.16 (moderately high plaque burden) [Figure 2], and 4.90 (low plaque burden) based on Agatston et al. criteria. The mean CAC score in cases was 11.14 ± 43.34. As none of the control had CAC and the score of all the subjects was zero.

Table 1: Recommended calcium score guidelines

| Calcium score | Plaque burden | Probability of significant CAD | Implications for CV risk | Recommendations |
|---------------|---------------|-------------------------------|--------------------------|-----------------|
| 0             | No identifiable atherosclerotic plaque | Very low generally <5% | Very low | Reassure patient while discussing general public health guidelines for primary prevention of CVD |
| 1–10          | Minimal identifiable plaque burden | Very unlikely, <10% | Low | Discuss general public health guidelines for primary prevention of CVD |
| 11–100        | Definite, at least mild atherosclerotic plaque burden | Mild or minimal, coronary stenoses likely | Moderate | Counsel about risk-factor modification, strict adherence to NCEP primary prevention cholesterol guidelines |
| 101–400       | Definite, at least moderate atherosclerotic plaque burden | Nonobstructive CAD highly likely, although atherosclerotic obstructive disease possible | Moderately high | Institute risk-factor modification and secondary prevention NCEP cholesterol guidelines. Consider exercise testing for further risk stratification |
| >400          | Extensive atherosclerotic plaque burden | High likelihood of at least one significant stenosis (≥90%) | High | Institute very aggressive risk-factor modification. Consider exercise or stress pharmacologic stress imaging to evaluate coronary stenosis for inducible ischemia |

Characteristics of patients with coronary artery calcification
The patients with CAC had significantly lower serum calcium levels (albumin corrected), as compared to the patients without CAC. No other parameter was significantly different in the two groups [Table 3]. The presence of CAC had a significant negative correlation with serum calcium levels (albumin corrected). No other parameter had a significant correlation with CAC [Table 4].

DISCUSSION
We found coronary plaques in 10% of the individuals with SIH, whereas none of the individuals in age and sex matched control group had coronary plaques. Our pilot data showed an increase in IMT at carotid, renal as well as abdominal aorta in patients with SIH.[14,15] In our previous study we found no significant association with any of the biochemical parameter,[13] whereas in the present study inverse correlation was found between corrected serum calcium and coronary calcium score. The concept of relative hypoparathyroidism and increased cardiovascular risk has been previously explored in the patients with renal failure.[25] In patients on dialysis, hyperphosphatemia is an independent risk factor for CVD.[6] Contrarily, both high as well as low calcium and PTH levels have been associated...
with increased cardiovascular mortality.\cite{2,22,23} While planning study we hypothesized that hyperphosphatemia in the patients with SIH may result in higher CIMT as it can induce the production of bone-forming proteins in the vascular smooth muscle and later deposition of calcium in the vascular smooth muscle cells leads to vascular calcification.\cite{9,10} Furthermore, transient hypercalcemia occur during the course of treatment of hypoparathyroidism may also elevate the calcium phosphate product and promote vascular calcification.\cite{9} In our study, low calcium level was associated with atherosclerotic plaques. However, high phosphate and low PTH levels did not account for increased cardiovascular risk in our study. The apparent relationship remains unexplained. The possible explanation for the increased cardiovascular risk and low calcium could be related to the severity of disease itself. The other reason might be that the patients with low serum calcium were receiving higher calcium supplementation dose though this was not documented. The nonskeletal risks of calcium supplements appear to outweigh any skeletal benefits of calcium supplementation.\cite{24} In meta-analyses of three placebo-controlled trials, calcium and Vitamin D increased the risk of myocardial infarction (relative risk 1.21 [95% confidence interval [CI] 1.01–1.44], \(P = 0.04\)), stroke (1.20 [1.00–1.43], \(P = 0.05\)), and the composite of myocardial infarction or stroke (1.16 [1.02–1.32], \(P = 0.02\)).\cite{25} On the other hand, another recent collaborative meta-analysis of randomized controlled trials found that, the current evidence does not support the hypothesis that the calcium supplementation with or without Vitamin D increases the risk of myocardial infarction or all-cause mortality risk in elderly women.\cite{26} Therefore, the hypothesis of calcium supplementation and increased cardiovascular risk is still a debated one with little evidence existing for plausible biological mechanisms to link calcium supplement use with adverse cardiovascular outcomes.\cite{27} 1, 25 dihydroxy vitamin D is deficient in the patients with hypoparathyroid, but the data on its deficiency and its supplementation in association with the cardiovascular mortality is not available. The relative risk of CVD death

Table 3: Characteristics of the patients with and without CAC

| Parameters                          | Cases with negative CAC score | Cases with positive CAC score | \(P\) |
|-------------------------------------|-------------------------------|-------------------------------|-------|
| Intact parathyroid hormone (ng/L)  | 7.6±4.2                      | 6.1±1.1                      | 0.49  |
| Serum calcium (mmol/L)              | 1.8±0.2                      | 1.6±0.2                      | 0.08  |
| Corrected serum calcium (mmol/L)    | 1.8±0.2                      | 1.4±0.2                      | 0.02  |
| Serum phosphorus (mmol/L)           | 2.0±0.5                      | 2.1±0.3                      | 0.21  |
| Glucose (mmol/L)                    | 5.4±0.9                      | 5.5±0.6                      | 0.73  |
| Serum albumin (g/L)                 | 43±5.0                       | 48±1.0                       | 0.13  |
| 25(OH) D (nmol/L)                   | 68.3±22.8                    | 56.8±25.0                    | 0.60  |
| TC (mmol/L)                         | 4.3±0.6                      | 4.9±0.3                      | 0.10  |
| HDL (mmol/L)                        | 1.2±0.2                      | 1.4±0.3                      | 0.19  |

CAC: Coronary artery calcification, TC: Total cholesterol, HDL: High density lipoprotein, 25(OH) D: 25-hydroxy Vitamin D

Table 4: The correlation of each parameter with CAC score

| Variables                             | Correlation with CAC score | \(P\) |
|---------------------------------------|----------------------------|-------|
| Product of serum calcium and serum phosphorus | -0.82                      | 0.67  |
| Intact parathyroid hormone             | -0.46                      | 0.810 |
| Serum calcium                          | -0.27                      | 0.14  |
| Corrected serum calcium                | -0.36                      | 0.05  |
| Serum phosphorus                       | 0.08                       | 0.67  |
| Fasting plasma glucose                 | 0.17                       | 0.38  |
| Serum albumin                          | 0.28                       | 0.14  |
| TC                                     | 0.04                       | 0.85  |
| HDL                                    | 0.19                       | 0.32  |
| Age                                    | 0.03                       | 0.89  |
| BMI                                    | 0.32                       | 0.08  |
| 25(OH) D                               | 0.001                      | 0.997 |
| Systolic blood pressure                | 0.313                      | 0.09  |
| Diastolic blood pressure               | 0.06                       | 0.77  |
| Low density lipoprotein-cholesterol   | 0.25                       | 0.19  |
| Triglycerides                          | 0.03                       | 0.86  |

CAC: Coronary artery calcification, TC: Total cholesterol, HDL: High density lipoprotein, BMI: Body mass index, 25(OH) D: 25-hydroxy Vitamin D
is 1.41 (95% CI 1.18, 1.68) greater in the lowest quintile of plasma 25-hydroxy Vitamin D (25(OH) D) according to meta-analysis of prospective cohort studies. Although several trials with cardiovascular endpoints are in progress, these are using pharmacological doses. In view of the potential toxicity of pharmacological doses, there remains a need for long-term trials of physiological doses of D2 and D3 with CVD incidence as the primary outcome. In our study, we found no difference in Vitamin D levels (25(OH) D) in the patients with or without CAC.

However, the cardiovascular risk as assessed by CAC was clearly higher in the patients with SIH. The pathophysiological basis for this increased risk need to be delineated. Maybe larger studies may throw more light on this relationship.

A small number of subjects is one of the limitations of this study, but the objective assessment by CAC is one of the greatest strengths of this study.

CONCLUSION

The vascular risk score is increased in the patients with SIH as assessed by coronary calcium score measured by MDCT. Low serum calcium levels might be a predisposing factor for this increased risk. More data is needed to substantiate these findings.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Bhadada SK, Bhansali A, Upreti V, Subbiah S, Khandelwal N. Spectrum of neurological manifestations of idiopathic hypoparathyroidism and pseudohypoparathyroidism. Neurol India 2011;59:586-9.
2. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 2008;52:519-30.
3. Staude H, Jeske S, Schmitz K, Warncke G, Fischer DC. Cardiovascular risk and mineral bone disorder in patients with chronic kidney disease. Kidney Blood Press Res 2013;37:68-83.
4. Kinata N, Albert JM, Akiba T, Yamazaki S, Kawaguchi T, Fukuhara S, et al. Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: The Japan dialysis outcomes and practice patterns study. Hemodial Int 2007;11:340-8.
5. Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, Goldsmith D. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009;24:1506-23.
6. Palmer SC, Hayen A, Macaskill P, Pellegreni F, Craig JC, Elder GJ, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: A systematic review and meta-analysis. JAMA 2011;305:1119-27.
7. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005;16:1788-93.
8. Abe M, Okada K, Soma M. Mineral metabolic abnormalities and mortality in dialysis patients. Nutrients 2013;5:1002-23.
9. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004;15:2959-64.
10. Ketteler M, Giachelli C. Novel insights into vascular calcification. Kidney Int Suppl 2006;70:S5-9.
11. Drüke TB, Massy ZA. Advanced oxidation protein products, parathyroid hormone and vascular calcification in uremia. Blood Purif 2002;20:494-7.
12. Galassi A, Spiegel DM, Bellasi A, Block GA, Raggi P. Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrol Dial Transplant 2006;21:3215-22.
13. Hunter DJ, Reddy IS. Noncommunicable diseases. N Engl J Med 2013;369:1336-43.
14. Gupta Y, Bhadada SK, Shah VN, Upreti V, Bhansali A, Jain S, et al. Carotid intima media thickness in patients with sporadic idiopathic hypoparathyroidism: A pilot study. Endocr J 2012;59:555-9.
15. Meena D, Prakash M, Gupta Y, Bhadada SK, Khandelwal N. Carotid, aorta and renal arteries intima-media thickness in patients with sporadic idiopathic hypoparathyroidism. Indian J Endocrinol Metab 2015;19:262-6.
16. Cohen GI, Aboufakher R, Bess R, Frank J, Othman M, Doan D, et al. Relationship between carotid disease on ultrasound and coronary artery disease on CT angiography. JACC Cardiovasc Imaging 2013;6:1160-7.
17. Polonsky TS, Blumenthal RS, Greenland P. Coronary artery calcium score. JAMA 2014;312:837-8.
18. Detrano RC, Anderson M, Nelson J, Wong ND, Carr JJ, McNitt-Gray M, et al. Coronary calcium measurements: Effect of CT scanner type and calcium measure on rescan reproducibility – MESA study. Radiology 2005;236:477-84.
19. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827-32.
20. Rumberger JA, Brundage BH, Rader DJ, Kondos G. Electron beam computed tomographic coronary calcium scanning: A review and guidelines for use in asymptomatic persons. Mayo Clin Proc 1999;74:243-52.
21. O’Rourke RA, Brundage BH, Froelicher VE, Greenland P, Grundy SM, Hachamovitch R, et al. American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. J Am Coll Cardiol 2000;36:326-40.
22. Guh JY, Chen HC, Chuang HY, Huang SC, Chien LC, Lai YH. Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. Am J Kidney Dis 2002;39:1245-54.
23. Foley RN, Parfrey PS, Harnett JD, Kent GM, Hu L, O’Dea R, et al. Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 1996;16:386-93.
24. Reid IR. Cardiovascular effects of calcium supplements. Nutrients 2013;5:2522-9.
25. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: Reanalysis of the Women’s Health Initiative limited access
26. Lewis JR, Radavelli-Bagatini S, Rejnmark L, Chen JS, Simpson JM, Lappe JM, et al. The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: A collaborative meta-analysis of randomized controlled trials.

27. Spence LA, Weaver CM. Calcium intake, vascular calcification, and vascular disease. Nutr Rev 2013;71:15-22.

28. Fry CM, Sanders TA. Vitamin D and risk of CVD: A review of the evidence. Proc Nutr Soc 2015;74:245-57.